Wrapmanager Inc. Sells 2,051 Shares of Novo Nordisk A/S $NVO

Wrapmanager Inc. lessened its position in Novo Nordisk A/S (NYSE:NVO) by 28.6% during the second quarter, Holdings Channel reports. The fund owned 5,113 shares of the company’s stock after selling 2,051 shares during the period. Wrapmanager Inc.’s holdings in Novo Nordisk A/S were worth $353,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Jennison Associates LLC boosted its holdings in shares of Novo Nordisk A/S by 0.3% in the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after purchasing an additional 63,341 shares in the last quarter. Kingstone Capital Partners Texas LLC lifted its position in Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after buying an additional 10,001,898 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Novo Nordisk A/S by 11.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,692,554 shares of the company’s stock worth $395,291,000 after buying an additional 576,900 shares in the last quarter. Sustainable Growth Advisers LP grew its position in Novo Nordisk A/S by 3.8% during the first quarter. Sustainable Growth Advisers LP now owns 5,543,246 shares of the company’s stock valued at $384,923,000 after acquiring an additional 202,443 shares during the last quarter. Finally, Nuveen LLC bought a new position in Novo Nordisk A/S during the first quarter valued at approximately $370,272,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $49.12 on Friday. The company’s fifty day simple moving average is $54.69 and its two-hundred day simple moving average is $61.14. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $112.52. The firm has a market cap of $219.32 billion, a PE ratio of 13.49, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.74 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research reports. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target for the company in a research note on Wednesday, August 13th. Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Finally, Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.